Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Añadir filtros








Intervalo de año
1.
Rev. Soc. Bras. Med. Trop ; 52: e20180323, 2019. graf
Artículo en Inglés | LILACS | ID: biblio-1003132

RESUMEN

Abstract We report the case of a 32-year-old man from Rio de Janeiro, who was infected in the Amazon region of Brazil by Leishmania (Viannia) naiffi. Generally, patients with L. naiffi cutaneous leishmaniasis exhibit a good therapeutic response to either pentavalent antimonials or pentamidine. However, after pentamidine treatment, this patient's infection evolved to therapeutic failure. To understand this clinical outcome, we investigated the presence of the Leishmania RNA virus (LRV) in parasites isolated from the cutaneous lesion; herein, we discuss the possible association between a poor response to pentamidine therapy and the presence of the LRV.


Asunto(s)
Humanos , Masculino , Adulto , Pentamidina/uso terapéutico , Virus ARN/genética , Tripanocidas/uso terapéutico , Leishmaniasis Cutánea/tratamiento farmacológico , Leishmania/virología , Pentamidina/efectos adversos , Tripanocidas/efectos adversos , Reacción en Cadena de la Polimerasa , Insuficiencia del Tratamiento
2.
In. Leäo, Raimundo Nonato Queiroz de; Bichara, Cléa Nazaré Carneiro; Miranda, Esther Castello Branco Mello; Carneiro, Irna Carla do Rosário de Souza; Abdon, Nagib Ponteira; Vasconcelos, Pedro Fernando da Costa; Silva, Bibiane Monteiro da; Paes, Andréa Luzia Vaz; Marsola, Lourival Rodrigues. Doenças Infecciosas e Parasitárias: Enfoque Amazônico. Belém, Cejup:Universidade do Estado do Pará:Instituto Evandro Chagas, 1997. p.619-30.
Monografía en Portugués | LILACS | ID: lil-248950
3.
Rev. Soc. Bras. Med. Trop ; 29(5): 477-81, Sept.-Oct. 1996.
Artículo en Portugués | LILACS | ID: lil-187192

RESUMEN

Ten patients with mucosal lesions caused by American tegumental leishmaniasis were treated with pentamidine isethionate at the dose 4 mg/kg on alternate days by the intravenous route. The mean posology was 2,140 mg. Healing of the lesions occurred in 9 (90 per cent) of the patients who completed treatment. There was no recurrence during a follow-up time of 1 to 24 months (mean, 7,7 months). One patient discontinued treatment before healing of the lesion because be developed diabetes mellitus. In 3 (30 per cent) patients, blood exams showed increased urea and creatinine levels and leucopenia, which were corrected by increasing the interval between administrations of the drug. Pentamidine isethionate is efficient in bringing about cicatrization of the lesions but needs further evaluation in terms of its value in preventing recurrence.


Asunto(s)
Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Antiprotozoarios/uso terapéutico , Leishmaniasis Cutánea/tratamiento farmacológico , Membrana Mucosa/patología , Pentamidina/uso terapéutico , Leishmaniasis Cutánea/patología , Pentamidina/efectos adversos
4.
Rev. Soc. Bras. Med. Trop ; 28(4): 405-7, Oct.-Dec. 1995.
Artículo en Inglés | LILACS | ID: lil-187131

RESUMEN

The authors report a case of a male patient from Bacabal, MA with diffuse cutaneous leishmaniasis (DCL), for at least nine years, with 168 lesions on his body. These were tumour-like nodules with some ulceration. He used pentavalent antimonial (glucantime) and an association of gamma interferon plus glucantime with improvement of the lesions but relapsed later. Recently, pentamidine isethionate (pentacarinat) was given a dosage of 4mg/kg/weight/day on alternate days for 20 applications. After 3 months a similar course of 10 application was given 2 times. Later he developed diabetic signs with weight loss of 10kg, polydypsia, polyuria and xerostomia. The lower limbs lesions showed signs of activity. Blood glucose levels normalised and remain like this at moment. Attention is drawn to the fact that pentamidine isethionate should be used as a therapy option with care, obeying rigorous laboratory controls including a glucose tolerance test.


Asunto(s)
Humanos , Masculino , Adulto , Antiprotozoarios/efectos adversos , Diabetes Mellitus/inducido químicamente , Leishmaniasis Cutánea Difusa/complicaciones , Pentamidina/efectos adversos , Antiprotozoarios/administración & dosificación , Leishmaniasis Cutánea Difusa/tratamiento farmacológico , Pentamidina/administración & dosificación , Factores de Tiempo
5.
An. bras. dermatol ; 65(4): 198-200, jul.-ago. 1990. ilus
Artículo en Portugués | LILACS | ID: lil-87992

RESUMEN

Os autores relatam os resultados obtidos no tratamento de 63 casos de leishmaniose tegumentar americana empregando o metanossulfonato de pentamidina (Lomidine) em dose única e endovenosa. Na dose de 120 a 480 mg em 100 a 250 ml de soro glicosado a 5%, a eficâcia foi de 76%. Considerando as reaçöes colaterais e as contra-indicaçöes da pentamidina, recomendam a sua utilizaçäo somente em alguns casos de recidiva ou rebeldes ao tratamento antimonial


Asunto(s)
Humanos , Masculino , Femenino , Inyecciones Intravenosas , Leishmaniasis Mucocutánea/tratamiento farmacológico , Pentamidina/terapia , Pentamidina/administración & dosificación , Pentamidina/efectos adversos
6.
Artículo en Inglés | IMSEAR | ID: sea-92190

RESUMEN

Five cases of persistent hyperglycaemia requiring insulin therapy following pentamidine treatment for Indian kala-azar are being reported.


Asunto(s)
Adulto , Niño , Humanos , Hiperglucemia/etiología , Insulina/uso terapéutico , Leishmaniasis/tratamiento farmacológico , Masculino , Pentamidina/efectos adversos
7.
An. bras. dermatol ; 63(6): 439-42, nov.-dez. 1988. tab
Artículo en Portugués | LILACS | ID: lil-60750

RESUMEN

As principais razöes para a escolha da pentamidina no presente ensaio terapêutico foram a alta taxa de recidiva de casos de forma mucosa de leishmaniose tegumentar com o tratamento pelos antimoniais pentavalentes e o fato deste medicamento ter sido usado com sucesso na forma cutânea da doença. Seis pacientes com forma mucosa de leishmaniose tegumentar diagnosticados clinicamente por exame dermato-otorrinolaringológico, reaçäo intradérmica de Montenegro, cultura inoculaçäo em hamster e esfregaço de material obtido das lesöes, exame histopatológico e pesquisa de anticorpos circulantes, foram tratados com pentamidina na dose de 200 mg em dias alternados, com dose total entre 2,3 a 5,9g, de acordo com a clínica. Houve cura clínica e parasitológica de cinco casos, com acompanhamento variando de 12 a 24 meses após o tratamento. No único caso de falha, tratava-se de um paciente que também näo respondeu ao tratamento com Glucantime. Entre os efeitos colaterais estäo um caso de diabetes mellitus, alteraçöes transitórias de glicemia em dois casos e abscesso glúteo em um, concluindo-se ser boa a resposta terapêutica à pentamidina dos casos da forma mucosa de leishmaniose tegumentar


Asunto(s)
Adulto , Persona de Mediana Edad , Humanos , Masculino , Femenino , Leishmaniasis/tratamiento farmacológico , Pentamidina/uso terapéutico , Anticuerpos/análisis , Leishmania braziliensis/inmunología , Leishmaniasis/patología , Pentamidina/administración & dosificación , Pentamidina/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA